Antibody-mediated rejection, commonly known as AMR, refers to organ rejection that occurs when antibodies produced by the patient's immune system target donor tissues following a transplant. AMR stems from preformed or de novo donor-specific antibodies that activate the complement system and stimulate cell-mediated immune responses. AMR has emerged as a significant barrier to long-term allograft survival as it accounts for approximately 10-20% of early graft losses and up to 30% of late graft failures.
The global antibody-mediated rejection market is primarily driven by the growing number of organ transplantation procedures around the world. Solid organ transplantations such as kidney, liver, heart, and lung are associated with life-long immunosuppressive therapy which elevates the risk of AMR. Furthermore, advancements in immunosuppressive drugs and improved detection techniques have enabled high-quality organ transplantation leading to an increase in demand. According to the Global Observatory on Donation and Transplantation, over 142,000 solid organ transplant procedures were performed globally in 2021.
The antibody-mediated rejection market is estimated to be valued at USD 126.5 Mn in 2024 and is expected to reach USD 291.1 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.64% from 2024 to 2031.
Key Takeaways

Key players operating in the antibody-mediated rejection market are Alexion Pharmaceuticals, Novartis, Bristol-Myers Squibb, Roche, and Pfizer.
The rising number of solid organ transplant procedures performed annually is a major factor fueling the demand for anti-rejection drugs to treat AMR. As per estimates, over 150,000 solid organ transplants are projected to be carried out globally by 2029.
Advancements in diagnostic capabilities with the development of novel assays and reliable biomarkers have enabled early detection of Antibody-Mediated Rejection Market, allowing timely intervention. Techniques such as Luminex single-antigen beads assays and antibody secretion assays have demonstrated high diagnostic accuracy.
Market Trends

Improved long-term outcomes of transplantation with monoclonal and polyclonal antibody desensitization protocols: Studies have shown reduced incidence and severity of AMR with pre-transplant treatments using intravenous immunoglobulin and antibodies targeting donor-specific .
Increasing focus on combination therapies leveraging mechanisms of action: Combining drugs targeting different pathways such as complement inhibition, lymphocytes depletion, and plasma cell differentiation holds promise for durable AMR suppression.
Market Opportunities

Burgeoning health expenditures in emerging economies are promoting greater access to organ transplantation and anti-rejection therapies.
Novel agents in development such as BIVV009, a C5 inhibitor, may offer advantages over existing treatment options and drive market growth once approved.
Impact of COVID-19 on the Antibody-mediated Rejection Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Antibody-mediated Rejection market. The nationwide lockdowns imposed restrictions on non-essential medical services and elective surgeries which led to cancellation or postponing of many organ transplant procedures during the peak times of the pandemic. This negatively affected the demand for Antibody-mediated Rejection drugs. However, the need for immunosuppressant therapies for transplant patients did not reduce. Organ transplant recipients as well as patients undergoing other long term immunosuppressive treatments were at higher risk of severe COVID infections. This triggered increased utilization of Antibody-mediated Rejection drugs to safely continue immunosuppression in high risk patients without compromising recovery.
With vaccination drives and easing of lockdowns globally, organ transplant activities have resumed. The demand is expected to rise steadily as the backlog of transplant cases is addressed. Pharmaceutical companies are innovating therapeutic strategies to effectively manage Antibody-mediated Rejection while protecting transplant recipients from COVID infections. Telehealth and remote patient monitoring solutions are supportingcontinuity of care. While short term growth was impacted, the long term growth prospects for the Antibody-mediated Rejection market remain promising given the growing prevalence of organ failure cases worldwide and increased focus on healthcare resilience against future pandemics.
In terms of geographical concentration, North America accounts for the largest share of the global Antibody-mediated Rejection market in terms of value. This is attributed to the availability of state-of-the-art healthcare facilities along with extensive coverage of immunosuppressive therapies under medical insurance in the region. Asia Pacific is identified as the most opportunistic market and is expected to witness the fastest growth during the forecast period owing to rising healthcare investments, growing incidence of chronic diseases leading to organ failure along with a steadily expanding patient pool in emerging countries.

Get More Insights On - Antibody-mediated Rejection Market

Get this Report in Japanese Language: 抗体介在性拒絶反応市場

Get this Report in Korean Language: 항체 매개 거부 시장

Author Bio:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )